Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.

Abstract

The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to… (More)
DOI: 10.1111/bjh.12256

Topics

6 Figures and Tables

Slides referencing similar topics